Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹2,820 cr of revenue in its latest quarter (Q2 FY27) and kept 11.5% of sales as profit.
Healthier than 59% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 37–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 65
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in EMCURE?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 5%, taken from a generic assumption, not this company's history. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹2,820 cr |
| Other Income | ₹3 cr |
| Total Income | ₹2,824 cr |
| Cost of Materials | ₹642 cr |
| Purchases of Stock-in-Trade | ₹625 cr |
| Inventory Change (±) | ₹-125 cr |
| Employee Benefit Expense | ₹435 cr |
| Finance Costs | ₹36 cr |
| Depreciation & Amortisation | ₹110 cr |
| Other Expenses | ₹656 cr |
| Total Expenses | ₹2,378 cr |
| Profit before Tax | ₹446 cr |
| Tax Expense | ₹121 cr |
| Net Profit | ₹325 cr |
| Net margin on total income | 11.5% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 2,470 cr | 2,580 cr | 2,820 cr |
| Total income | 2,474 cr | 2,583 cr | 2,824 cr |
| Expenses | 2,143 cr | 2,189 cr | 2,378 cr |
| Profit before tax | 341 cr | 394 cr | 446 cr |
| Tax | 97 cr | 101 cr | 121 cr |
| Net profit (owners' share) | 243 cr | 294 cr | 326 cr |
| Net margin (owners' share, on revenue) | 9.9% | 11.4% | 11.5% |
| EPS (₹) | 12.84 | 15.50 | 17.16 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,770 | ₹4.25 L cr | 53.3 | 8.9% | 12.3% | — |
| Divi's Laboratories Limited | ₹10,064 | ₹2.67 L cr | 74.1 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,650 | ₹1.77 L cr | 82.7 | 11.6% | 10.7% | — |
| Laurus Labs Limited | ₹2,323 | ₹1.26 L cr | 71.1 | 29.1% | 20.0% | — |
| Zydus Lifesciences Limited | ₹1,241 | ₹1.24 L cr | 33.2 | 13.9% | 11.7% | — |
| Dr. Reddy's Laboratories Limited | ₹1,368 | ₹1.14 L cr | 30.8 | 9.5% | 10.6% | — |
| Cipla Limited | ₹1,397 | ₹1.13 L cr | 32.2 | 9.9% | 11.9% | — |
| Mankind Pharma Limited | ₹2,475 | ₹1.02 L cr | 35.9 | 16.2% | 16.4% | — |
| Aurobindo Pharma Limited | ₹1,695 | ₹97,502 cr | 23.7 | 10.9% | 11.3% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹3.6 / share | 4 Sep 2026 |
| Dividend | ₹3 / share | 14 Aug 2025 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 20 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.